#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.MedicalEntity|DCT|MedicalEntity
#T_RL=webanno.custom.TLINK|TLINK|BT_webanno.custom.MedicalEntity


#Text=30.07.2023:
#Text=Vedvarende sykdomsaktivitet.
1-1	0-10	30.07.2023	_	_	_	_	
1-2	10-11	:	_	_	_	_	
1-3	12-22	Vedvarende	OVERLAP[1]	CONDITION[1]	_	_	
1-4	23-39	sykdomsaktivitet	OVERLAP[1]	CONDITION[1]	_	_	
1-5	39-40	.	_	_	_	_	

#Text=DAS28-score 4.2.
2-1	41-46	DAS28	OVERLAP	CONDITION	_	_	
2-2	46-47	-	_	_	_	_	
2-3	47-52	score	_	_	_	_	
2-4	53-56	4.2	_	_	_	_	
2-5	56-57	.	_	_	_	_	

#Text=Starter Humira etter negative screeningprøver.
3-1	58-65	Starter	_	_	_	_	
3-2	66-72	Humira	AFTER	TREATMENT	_	_	
3-3	73-78	etter	_	_	_	_	
3-4	79-87	negative	OVERLAP[2]	CONDITION[2]	_	_	
3-5	88-103	screeningprøver	OVERLAP[2]	CONDITION[2]	_	_	
3-6	103-104	.	_	_	_	_	

#Text=Opprettholder Methotrexate.
4-1	105-118	Opprettholder	AFTER[3]	TREATMENT[3]	_	_	
4-2	119-131	Methotrexate	AFTER[3]	TREATMENT[3]	_	_	
4-3	131-132	.	_	_	_	_	

#Text=Prednisolon økes forbigående til 10mg.
5-1	133-144	Prednisolon	AFTER[4]	TREATMENT[4]	_	_	
5-2	145-149	økes	AFTER[4]	TREATMENT[4]	_	_	
5-3	150-161	forbigående	_	_	_	_	
5-4	162-165	til	_	_	_	_	
5-5	166-170	10mg	_	_	_	_	
5-6	170-171	.	_	_	_	_	

#Text=Ny vurdering om 8 uker.
6-1	172-174	Ny	_	_	_	_	
6-2	175-184	vurdering	AFTER	TREATMENT	BEFORE|BEFORE|BEFORE	5-1[4_0]|4-1[3_0]|3-2	
6-3	185-187	om	_	_	_	_	
6-4	188-189	8	_	_	_	_	
6-5	190-194	uker	_	_	_	_	
6-6	194-195	.	_	_	_	_	
